Open Access<p>Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis</p>
Author(s) -
Takashi Sügimura,
Shinji Asada,
Yuki Endo,
Takehisa Kawata,
Masafumi Fukagawa,
Tadao Akizawa
Publication year - 2020
Publication title -
international journal of nephrology and renovascular disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.846
H-Index - 27
ISSN - 1178-7058
DOI - 10.2147/ijnrd.s243210
Subject(s) - medicine , hemodialysis , secondary hyperparathyroidism , hyperparathyroidism , calcium , urology , parathyroid hormone
Evocalcet is a novel oral calcimimetic drug that has demonstrated similar efficacy to cinacalcet in regulating serum parathyroid hormone (PTH), calcium, and phosphate levels, with fewer upper gastrointestinal tract-related adverse drug reactions (ADRs) in patients with secondary hyperparathyroidism undergoing hemodialysis in Japan. We investigated the efficacy and safety of once-daily oral evocalcet under different dialysate calcium concentrations.